NCT05676333

Secukinumab in Active Non-segmental Vitiligo

Pilot Trial to Determine the Efficacy of Secukinumab in Active Non-segmental Vitiligo

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: University Hospital, Ghent · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Vitiligo is an acquired autoimmune skin disorder which leads to cutaneous depigmentations. A lot of progress has been made to unravel the pathophysiology of vitiligo. Several independent studies confirmed the elevated values of IL-17 in the serum of vitiligo patients and higher IL-17 values have been linked to a higher affected body surface area and a longer disease duration. The study will be a pilot trial with secukinumab in patients with active, non-segmental vitiligo. All patients will receive the active compound (= no placebo arm) as the purpose of the study is to investigate the potential efficacy of secukinumab in vitiligo.

Conditions

• Vitiligo
• Secukinumab

Interventions

Type	Name	Description
DRUG	Secukinumab

Timeline

• Start date: 2016-10-12
• Primary completion: 2017-12-16
• Completion: 2019-02-22
• First posted: 2023-01-09
• Last updated: 2023-02-10

Locations

1 site across 1 country: Belgium